[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002214950A1 - Determination of the ability of patients to respond to tumour treatment - Google Patents

Determination of the ability of patients to respond to tumour treatment

Info

Publication number
AU2002214950A1
AU2002214950A1 AU2002214950A AU1495002A AU2002214950A1 AU 2002214950 A1 AU2002214950 A1 AU 2002214950A1 AU 2002214950 A AU2002214950 A AU 2002214950A AU 1495002 A AU1495002 A AU 1495002A AU 2002214950 A1 AU2002214950 A1 AU 2002214950A1
Authority
AU
Australia
Prior art keywords
respond
patients
ability
determination
tumour treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214950A
Inventor
Ulrich Certa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2002214950A1 publication Critical patent/AU2002214950A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002214950A 2000-08-28 2001-08-20 Determination of the ability of patients to respond to tumour treatment Abandoned AU2002214950A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00118603 2000-08-28
EP00118603.0 2000-08-28
PCT/EP2001/009556 WO2002018633A2 (en) 2000-08-28 2001-08-20 Determination of the ability of patients to respond to tumour treatment

Publications (1)

Publication Number Publication Date
AU2002214950A1 true AU2002214950A1 (en) 2002-03-13

Family

ID=8169672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214950A Abandoned AU2002214950A1 (en) 2000-08-28 2001-08-20 Determination of the ability of patients to respond to tumour treatment

Country Status (7)

Country Link
US (1) US20030096237A1 (en)
EP (1) EP1337663A2 (en)
JP (1) JP2004507253A (en)
AR (1) AR030502A1 (en)
AU (1) AU2002214950A1 (en)
CA (1) CA2419578A1 (en)
WO (1) WO2002018633A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
US20050089899A1 (en) * 2003-08-28 2005-04-28 Daniel Birnbaum Identification of an ERBB2 gene expression signature in breast cancers
CA2585244C (en) 2004-10-28 2015-02-17 Otsuka Pharmaceutical Co., Ltd. Identification marker responsive to interferon therapy for renal cell cancer
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501782D0 (en) * 1995-05-12 1995-05-12 Landstinget I Oestergoetland Method of predicting the therapeutic response of a drug against a malignant tumor
US5998151A (en) * 1995-12-01 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase

Also Published As

Publication number Publication date
AR030502A1 (en) 2003-08-20
US20030096237A1 (en) 2003-05-22
WO2002018633A3 (en) 2003-06-05
EP1337663A2 (en) 2003-08-27
CA2419578A1 (en) 2002-03-07
WO2002018633A2 (en) 2002-03-07
JP2004507253A (en) 2004-03-11

Similar Documents

Publication Publication Date Title
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2001280440A1 (en) Treatment of human herpesviruses using hyperthermia
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2002303502A1 (en) Improved leads for the treatment of patients with chf
AU2002357830A1 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
AUPQ877300A0 (en) Topical treatment of skin
AU3896900A (en) Treatment of pain
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AU7106300A (en) Treatment of skin disorders
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
AU2002214950A1 (en) Determination of the ability of patients to respond to tumour treatment
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU2566201A (en) Compounds and methods for the treatment of pain
IL154011A0 (en) Treatment of wounds
AU1405001A (en) Treatment of diseases
AU3064800A (en) The therapeutic use of r-warfarin as anticoagulant
AU2002218977A1 (en) Novel marker for the diagnosis and therapy of tumours
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU7455300A (en) The band combined medical treatment of ion